Sarepta Therapeutics, Inc
Price
OptionsOpen the Sheet →FilingsNewest: Form 13G, stake over 5%, passiveNov 10 →InsidersNo open-market buys. 2 insiders sold $417,410, 0 of 2 sales on a 10b5-1 plan.→HoldersBlackRock 17.7%State Street 8.3%Vanguard Portfolio 7.8%→Financing →PeersClosest companies: RLAY, VRDN, ORIC→
From the filings
Figures
- Revenue
- $1.83Blast 12 months
- Net income
- −$114.6Mlast 12 months
- Operating cash flow
- $111.0Mlast 12 months
- Cash and equivalents
- $472.8Mat the last balance sheet
- Total debt
- $1.02Bat the last balance sheet
- Shares outstanding
- 107.2M shareson issue
Filings, newest first
- Nov 1013GStake over 5%, passive
- Nov 58-KResults of operations
- Nov 510-QQuarterly report
- Sep 238-KMaterial agreement
- Sep 84Insider trade
- Sep 84Insider trade
- Aug 713GStake over 5%, passive
- Aug 58-KResults of operations
- Aug 510-QQuarterly report
- Jul 278-KDirector or officer change
- Mar 210-KAnnual report